TELAVIC® 250 mg Tablets, Antiviral
Approval of Additional indication for Chronic Hepatitis C Genotype 2

Osaka, Japan, September 19, 2014---Mitsubishi Tanabe Pharma Corporation (President & Representative Director, CEO: Masayuki Mitsuka) announced today that the company obtained approval of an additional indication of chronic hepatitis C genotype 2 for TELAVIC® 250mg Tablets (generic name: telaprevir) (hereinafter, Telavic®).

Telavic®, an oral treatment of chronic hepatitis C, inhibits NS3-4A serine protease thereby suppresses the replication of hepatitis C virus (HCV). It has been used to treat patients with HCV genotype 1, which is approximately 70% of Japanese HCV carriers. Following the approval of the new indication, Telavic® became available for patients with HCV genotype 2, which consists of approximately 30% of Japanese patients with HCV.

There has been no effective treatment for patients with HCV genotype 2 in whom prior treatment by IFN-based therapy (pegylated interferon α + ribavirin, etc.) had failed. Now, the triple combination therapy with Telavic® (telaprevir + pegylated interferon α + ribavirin) becomes available for those patients.

By providing information for proper use, Mitsubishi Tanabe Pharma will contribute further to the treatment of patients with HCV.

<Contact for Inquiries>
Corporate Communications Department
Phone: +81 6-6205-5211